Pricing Log in Create free account
Friday 6 November 2026 Export LFWD’s income statement to Excel — free account

Lifeward Ltd.

LFWD Healthcare Medical Devices

Lifeward Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $22.0 million, down 14.1% from fiscal 2024.

Revenue
+15.7%
EPS
+40.8%
Free cash flow
−52.8%

Quarter to June 2026, against a year earlier

5.87 0.13 +2.26%
Market cap
$16.3M
P/E
0.0×
Fwd P/E
−0.8×
Dividend yield
—
F-score
4/9
Altman Z
−18.75
Beneish M
−3.19
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 45.66%

Capital & Financial Ratios $m

Size
Market Cap 16.25
Revenue ttm 21.82
Net income ttm (30.83)
Free cash flow ttm (17.10)
Net debt Q (0.94)
Valuation
P/E 0.00
Forward P/E (0.79) (negative: loss-making)
Price / sales 0.75
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.34
Financial health
Current ratio Q 2.33 (at or above 1.5: strong)
Debt / equity Q 0.70
Interest coverage Q (20.16)
Growth
Revenue growth Q +15.71% (above 0%: growing)
Operating income growth Q +36.74% (above 0%: growing)
EPS, this year +56.92% (at or above 15%: strong)
EPS, next year A +76.32% (at or above 15%: strong)
Revenue, next year A +14.55% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +65.57% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.8×, against a ten-year median of 1.1×; over the ten years it ranged from −6.2× in 2022 to 29.4× in 2016.
P/S against its own 10 years 15.62%
10-year low 10-year high
P/B against its own 10 years 60.02%
10-year low 10-year high
EV/Sales against its own 10 years 29.96%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 28 7 2 9
Receivables 3 6 6 8
Inventory 6 7 6 6
Other — — — 1
39 21 16 26
2023 2024 2025 Q'26
Payables 5 5 6 6
ST’ Debt — — 3 —
Other 2 2 1 2
12 10 12 11

Compound Annual Growth %

10y 5y 3y
Sales 19.39% 38.06% 58.72%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (8.71%) (17.33%) (50.22%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −1.49 Actual −1.46

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY25 −3.00 −6.96 Miss by 3.96
Q4 FY25 −0.84 −3.60 Miss by 2.76
Q1 FY26 −0.34 −6.70 Miss by 6.36
Q2 FY26 −1.49 −1.46 Beat by 0.03
Q3 FY26 −0.53 — Reports 13 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (6.70) (4.12) — — —
’25 (5.52) (6.96) (2.40) (3.60) (17.16)
’24 (8.76) (6.00) (4.20) (20.77) (39.98)
’23 (5.88) (6.72) (10.92) (7.91) (31.08)
’22 (5.88) (5.88) (7.56) (7.56) (26.04)
’21 (6.72) (5.88) (5.04) (5.04) (22.68)
’20 (31.08) (18.48) (15.12) (11.76) (68.89)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 4 7 — — —
’25 5 6 6 5 22
’24 5 7 6 8 26
’23 1 1 4 7 14
’22 1 2 1 2 6
’21 1 1 2 1 6
’20 1 2 1 1 4
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (6) — — —
’25 (5) (4) (4) (4) (17)
’24 (8) (6) (4) (4) (22)
’23 (5) (4) (7) (4) (21)
’22 (6) (4) (5) (4) (18)
’21 (3) (3) (3) (3) (11)
’20 (4) (3) (3) (2) (13)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (6) — — —
’25 (5) (4) (4) (4) (17)
’24 (8) (6) (4) (4) (22)
’23 (5) (4) (7) (5) (21)
’22 (6) (4) (5) (4) (18)
’21 (3) (3) (3) (3) (12)
’20 (4) (3) (3) (2) (13)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 6 8 7 5 4 6 6 14 26 22 22 +15.8% 25 42 56 +36.5%
Gross margin, % 12.54 40.00 43.16 55.94 49.83 48.66 34.57 32.14 32.01 38.25 35.95 +25.7 pt
EBT (32) (25) (22) (16) (13) (13) (19) (22) (29) (20) (31) (5.3%)
EBT margin, % (553.76) (317.27) (331.25) (318.98) (294.22) (211.90) (346.62) (159.85) (112.61) (90.63) (141.51) +463.1 pt
Net income (33) (25) (22) (16) (13) (13) (20) (22) (29) (20) (31) (5.3%)
Per share, $
Per share, $ Revenue 931.59 807.60 374.00 71.04 23.40 10.46 7.42 19.50 35.43 18.98 7.80 (35.1%)
Earnings (5,187.52) (2,562.26) (1,239.12) (226.82) (68.89) (22.68) (26.04) (31.08) (39.98) (17.16) (16.82) (47.0%)
Cash flow (4,370.95) (2,339.79) (844.23) (215.96) (67.07) (20.10) (24.10) (29.08) (29.98) (14.49) (6.11) (47.0%)
Capex (69.37) (2.19) (0.74) (0.32) (0.39) (0.08) (0.03) (0.11) 0.00 (0.01) (0.01) (61.2%)
Free cash flow (4,440.32) (2,341.98) (844.97) (216.28) (67.46) (20.18) (24.13) (29.20) (29.98) (14.51) (6.11) (47.1%)
Book value 1,311.11 386.15 111.14 157.14 116.00 156.65 91.80 65.45 26.02 7.24 4.37 (43.9%)
Shares, m 0 0 0 0 0 1 1 1 1 1 2 +78.5%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 6.76 2.93 0.98 2.55 4.74 9.88 8.54 3.83 0.59 0.36 0.75 4.1
P/B 4.81 6.12 3.29 1.15 0.96 0.66 0.69 1.14 0.80 0.96 1.34 2.1
EV/Sales 5.80 3.03 0.85 0.65 0.47 (4.75) (3.61) 1.96 0.40 0.42 0.84 0.5
EV/FCF (1.22) (1.04) (0.37) (0.21) (0.16) 2.46 1.11 (1.31) (0.47) (0.55) (1.07) (0.2)
Cash, $m
Cash, $m Operating cash flow (28) (22) (15) (15) (13) (11) (18) (21) (22) (17) (17) (5.3%)
Capex 0 0 0 0 0 0 0 0 — 0 0 (30.8%)
Free cash flow (28) (22) (15) (15) (13) (12) (18) (21) (22) (17) (17) (5.5%)
Balance, $m
Balance, $m Working capital 17 11 8 11 21 88 68 27 11 4 15 (15.4%)
Net debt (6) 1 (1) (9) (20) (88) (67) (28) (7) 0 (1) n/m
Shareholders’ equity 8 4 2 11 22 89 68 47 19 8 12 +0.2%
Returns, %
Returns, % ROA (113.38) (90.50) (114.61) (79.07) (49.49) (20.74) (23.16) (32.21) (61.79) (74.60) (99.81) +38.8 pt
ROIC (733.16) (305.99) (1,105.78) (588.47) (360.00) (468.84) (1,433.22) (80.09) (154.06) (139.70) (126.06) +593.5 pt
ROE (222.78) (413.09) (766.99) (244.42) (79.72) (22.92) (24.84) (38.60) (88.56) (146.12) (225.65) +76.7 pt
People
People Employees 94 65 58 50 49 51 56 108 80 81 — (1.6%)
Revenue/emp, $m 0.06 0.12 0.11 0.10 0.09 0.12 0.10 0.13 0.32 0.27 — +17.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Lifeward Ltd. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NNOX Nano-X Imaging Ltd. $19.6M — (loss-making) — (loss-making) +36.71% (above 0%: growing) n/m −21.37% (below 0%: shrinking) (1,050.87%) (1,334.91%) Compare
SNWV Sanuwave Health Inc. $19.4M 1.2× — (loss-making) −3.13% (below 0%: shrinking) n/m +86.75% (above 0%: growing) 76.23% (2.88%) Compare
PMI Flag Ship Acquisition Corp $19.3M — (loss-making) — (loss-making) +38.62% (above 0%: growing) n/m +46.79% (above 0%: growing) 20.85% (156.70%) Compare
ALUR Allurion Technologies, Inc. $16.7M — (loss-making) — (loss-making) −47.19% (below 0%: shrinking) n/m +65.98% (above 0%: growing) 41.70% (126.60%) Compare
LFWD Lifeward Ltd. $16.3M — (loss-making) — (loss-making) +15.71% (above 0%: growing) n/m −52.77% (below 0%: shrinking) 40.90% (62.69%)
ARAY Accuray Incorporated $14.8M — (loss-making) — (loss-making) −7.90% (below 0%: shrinking) n/m −138.30% (below 0%: shrinking) 0.00% (42.19%) Compare
CTSO Cytosorbents Corporation $14.5M — (loss-making) — (loss-making) +0.17% (above 0%: growing) n/m +64.90% (above 0%: growing) 73.18% (27.39%) Compare
RBOT Vicarious Surgical Inc. $14.3M — (loss-making) — — n/m +47.33% (above 0%: growing) 0.00% 0.00% Compare
HSCS HeartSciences Inc. $13.3M — (loss-making) — (loss-making) −46.15% (below 0%: shrinking) n/m +18.18% (above 0%: growing) 61.90% (139,957.14%) Compare
Median of peers $15.8M — — −3.13% — +47.06% 31.28% (84.39%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 25 September 2026

Ownership

Directors and executive officers, together 1.10%
Oramed Pharmaceuticals Inc. 44.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Lifeward Ltd. (LFWD) Latest News

14 Oct

Impact 4 · · GlobeNewswire

15 Sep

Impact 3 ·

31 Aug

Impact 3 ·

14 Aug

Impact 4 ·
Impact 3 ·

5 Aug

Impact 3 ·

7 Jul

Impact 4 ·

19 May

Impact 3 · · GlobeNewswire

17 May

Impact 3 · · Simply Wall St.

15 May

Impact 4 · · The Motley Fool transcript
Impact 4 · · Moby
Impact 4 · · GlobeNewswire
Impact 3 · · GuruFocus.com
Impact 3 · · Zacks

4 May

Impact 4 · · GlobeNewswire

25 Mar

Impact 4 · · GlobeNewswire

18 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · Associated Press Finance
Impact 4 · · GlobeNewswire

13 Mar

Impact 4 · · GlobeNewswire

11 Mar

Impact 4 · · GlobeNewswire

2 Mar

Impact 4 · · GlobeNewswire

26 Feb

Impact 4 · · Zacks Small Cap Research

25 Feb

Impact 4 · · GlobeNewswire

17 Feb

Impact 4 · · GlobeNewswire

13 Jan

Impact 4 · · GlobeNewswireSimply Wall St.BioPharma DiveSimply Wall St.MT NewswiresSimply Wall St.Simply Wall St.Clinical Trials Arena
Impact 4 · · PR Newswire

19 Dec

Impact 3 · · GlobeNewswire

17 Dec

Impact 4 · · GlobeNewswireMT NewswiresGuruFocus.comZacksMT NewswiresGuruFocus.comMT NewswiresMedical Device Network

3 Dec

Impact 4 · · GlobeNewswire
stockrow.com/LFWD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com